Edison Oncology and Apollomics Inc. Announce Treatment of First Patient For EO1001 (APL-122) in a Phase I/IIa Clinical Trial
September 30, 2021 07:10 ET
|
Apollomics, Inc.; Edison Oncology Holding Corp.
MENLO PARK, Calif., FOSTER CITY, Calif. and HANGZHOU, China, Sept. 30, 2021 (GLOBE NEWSWIRE) -- Edison Oncology Holding Corp. (“Edison Oncology”), a company established to develop new therapies...